RIPK3 and metabolic dysfunction-associated steatohepatitis: In mouse models of acetaminophen hepatotoxicity [163,165] and ethanol and dietary intoxication [99,165], concanavalin-A induced fulminant hepatitis [163], and NASH [101,102], an RIPK3−/− genotype, or treated with dabrafenib (an inhibitor of the active kinase BRAF oncogene, which also suppresses RIPK3 kinase activity) [166], provides considerable hepatoprotective effects against liver injury in virtually of all these mouse models.